FELIX YELOVICH: Open Payments
NPI 1114090982 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,267 in 100 payments from 14 companies in 2025. Trend: 2023 $2,130 · 2024 $2,160 · 2025 $2,267
Food & beverage: $2,267
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 36 | $668 |
| Janssen Biotech, Inc. | 23 | $538 |
| Madrigal Pharmaceuticals | 16 | $348 |
| Boston Scientific Corporation | 1 | $143 |
| Aimmune Therapeutics, Inc. | 4 | $114 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $93 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $81 |
| Ardelyx, Inc. | 3 | $65 |
| Phathom Pharmaceuticals, Inc. | 3 | $59 |
| Gilead Sciences, Inc. | 3 | $54 |
Products named: TREMFYA, REZDIFFRA, RINVOQ, OverStitch Endoscopic Suturing System, SKYRIZI, CREON, ENTYVIO, ZENPEP.
Industry payments across MD — which companies pay providers there.
